Piero Pollesello

List of Publications by Citations

Source: https://exaly.com/author-pdf/954500/piero-pollesello-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122 papers 4,708 citations

41 h-index 64 g-index

129 ext. papers

5,310 ext. citations

avg, IF

4.99 L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 122 | Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. <i>Journal of Magnetic Resonance Imaging</i> , 1995 , 5, 281-5 | 5.6 | 305 |
| 121 | Noninvasive in vivo quantitative assessment of fat content in human liver. <i>Journal of Hepatology</i> , 1997 , 27, 108-13 | 13.4 | 259 |
| 120 | Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. <i>International Journal of Cardiology</i> , 2012 , 159, 82-7 | 3.2 | 209 |
| 119 | Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca2+-binding glycoprotein. <i>Journal of Cell Biology</i> , 1986 , 103, 1615-23 | 7.3 | 131 |
| 118 | Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 37, 367-74 | 3.1 | 128 |
| 117 | Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018 , 39, 4243-4254 | 9.5 | 113 |
| 116 | Levosimendan is a mitochondrial K(ATP) channel opener. <i>European Journal of Pharmacology</i> , 2001 , 428, 311-4 | 5.3 | 103 |
| 115 | Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. <i>Journal of Biological Chemistry</i> , 2001 , 276, 9337-43 | 5.4 | 101 |
| 114 | Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 272-285 | 12.3 | 99 |
| 113 | The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. <i>International Journal of Cardiology</i> , 2015 , 191, 256-64 | 3.2 | 94 |
| 112 | A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. <i>British Journal of Pharmacology</i> , 2008 , 154, 41-50 | 8.6 | 81 |
| 111 | The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. <i>European Journal of Pharmacology</i> , 2004 , 486, 67-74 | 5.3 | 79 |
| 110 | Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. <i>International Journal of Cardiology</i> , 2016 , 222, 303-312 | 3.2 | 78 |
| 109 | Potassium-specific effects of levosimendan on heart mitochondria. <i>Biochemical Pharmacology</i> , 2004 , 68, 807-12 | 6 | 77 |
| 108 | The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. <i>Molecular and Cellular Biochemistry</i> , 2004 , 266, 87-107 | 4.2 | 75 |
| 107 | Inhibition of lipid peroxidation in isolated rat liver mitochondria by the general anaesthetic propofol. <i>Biochemical Pharmacology</i> , 1992 , 44, 391-3 | 6 | 74 |
| 106 | The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017 , 19, 1361-1378 | 12.3 | 73 |

(2013-2005)

| 105 | Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. <i>Cardiovascular Drug Reviews</i> , 2005 , 23, 71-98 | | 73 |
|-----|--|------|----|
| 104 | Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 479-91 | 5.8 | 73 |
| 103 | Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. <i>International Journal of Cardiology</i> , 2015 , 184, 323-336 | 3.2 | 70 |
| 102 | Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene. <i>Journal of Biological Chemistry</i> , 1997 , 272, 23784-91 | 5.4 | 66 |
| 101 | The cardioprotective effects of levosimendan: preclinical and clinical evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2007 , 50, 257-63 | 3.1 | 66 |
| 100 | Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 43, 555-61 | 3.1 | 65 |
| 99 | Levosimendan meta-analyses: Is there a pattern in the effect on mortality?. <i>International Journal of Cardiology</i> , 2016 , 209, 77-83 | 3.2 | 64 |
| 98 | The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. <i>British Journal of Pharmacology</i> , 2006 , 148, 696-702 | 8.6 | 59 |
| 97 | Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 342, 376-88 | 4.7 | 57 |
| 96 | Organic solvent systems for 31P nuclear magnetic resonance analysis of lecithin phospholipids: applications to two-dimensional gradient-enhanced 1H-detected heteronuclear multiple quantum coherence experiments. <i>Analytical Biochemistry</i> , 1997 , 245, 38-47 | 3.1 | 56 |
| 95 | Renal effects of levosimendan: a consensus report. Cardiovascular Drugs and Therapy, 2013, 27, 581-90 | 3.9 | 55 |
| 94 | Oxygen-derived free radical (ODFR) action on hyaluronan (HA), on two HA ester derivatives, and on the metabolism of articular chondrocytes. <i>Experimental Cell Research</i> , 1995 , 218, 79-86 | 4.2 | 54 |
| 93 | Structure of the 1-36 amino-terminal fragment of human phospholamban by nuclear magnetic resonance and modeling of the phospholamban pentamer. <i>Biophysical Journal</i> , 1999 , 76, 1784-95 | 2.9 | 53 |
| 92 | Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. <i>British Journal of Pharmacology</i> , 2007 , 150, 851-61 | 8.6 | 52 |
| 91 | Complex electrophysiological remodeling in postinfarction ischemic heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3036-E3044 | 11.5 | 51 |
| 90 | ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. <i>Current Opinion in Critical Care</i> , 2004 , 10, 436-41 | 3.5 | 48 |
| 89 | Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. <i>International Journal of Cardiology</i> , 2014 , 174, 360-7 | 3.2 | 47 |
| 88 | ORM-10103, a novel specific inhibitor of the Na+/Ca2+ exchanger, decreases early and delayed afterdepolarizations in the canine heart. <i>British Journal of Pharmacology</i> , 2013 , 170, 768-78 | 8.6 | 47 |

| 87 | The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. <i>International Journal of Cardiology</i> , 2016 , 218, 150-157 | 3.2 | 47 |
|----|---|------|----|
| 86 | Calcium sensitizers: What have we learned over the last 25 years?. <i>International Journal of Cardiology</i> , 2016 , 203, 543-8 | 3.2 | 46 |
| 85 | Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization. <i>European Journal of Pharmacology</i> , 2004 , 486, 1-8 | 5.3 | 45 |
| 84 | Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides. <i>Journal of Molecular and Cellular Cardiology</i> , 2003 , 35, 1055-61 | 5.8 | 44 |
| 83 | Structural determination of the acidic exopolysaccharide produced by a Pseudomonas sp. strain 1.15. <i>Carbohydrate Research</i> , 1999 , 315, 159-68 | 2.9 | 44 |
| 82 | Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. <i>Liver Transplantation</i> , 2014 , 20, 361-75 | 4.5 | 41 |
| 81 | Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 71, 1-9 | 3.1 | 39 |
| 80 | Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 48, 148-52 | 3.1 | 39 |
| 79 | A cellular UDP-glucose deficiency causes overexpression of glucose/oxygen-regulated proteins independent of the endoplasmic reticulum stress elements. <i>Journal of Biological Chemistry</i> , 2004 , 279, 21724-31 | 5.4 | 37 |
| 78 | Two inotropes with different mechanisms of action: contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 46, 369-76 | 3.1 | 37 |
| 77 | Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. <i>Cardiovascular Research</i> , 2002 , 56, 248-59 | 9.9 | 37 |
| 76 | Solution structure and main chain dynamics of the regulatory domain (Residues 1-91) of human cardiac troponin C. <i>Journal of Biological Chemistry</i> , 1998 , 273, 15633-8 | 5.4 | 36 |
| 75 | The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca2+-ATPase superinhibition and cardiac remodeling. <i>Circulation</i> , 2006 , 113, 995-1004 | 16.7 | 35 |
| 74 | Improved survival with simendan after experimental myocardial infarction in rats. <i>European Journal of Pharmacology</i> , 2001 , 419, 243-8 | 5.3 | 35 |
| 73 | Effects of levosimendan on the energy balance: preclinical and clinical evidence. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 53, 302-10 | 3.1 | 32 |
| 72 | Analysis of total lipid extracts from human liver by 13C and 1H nuclear magnetic resonance spectroscopy. <i>Analytical Biochemistry</i> , 1996 , 236, 41-8 | 3.1 | 32 |
| 71 | The Effect of a Novel Highly Selective Inhibitor of the Sodium/Calcium Exchanger (NCX) on Cardiac Arrhythmias in In Vitro and In Vivo Experiments. <i>PLoS ONE</i> , 2016 , 11, e0166041 | 3.7 | 32 |
| 70 | Selective Na(+) /Ca(2+) exchanger inhibition prevents Ca(2+) overload-induced triggered arrhythmias. <i>British Journal of Pharmacology</i> , 2014 , 171, 5665-81 | 8.6 | 31 |

| 69 | Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 617-624 | 3.9 | 30 | |
|----|---|-----|----|--|
| 68 | Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. <i>ESC Heart Failure</i> , 2017 , 4, 595-604 | 3.7 | 29 | |
| 67 | Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 129-35 | 2.6 | 29 | |
| 66 | Structure of the exopolysaccharide produced by Enterobacter amnigenus. <i>Carbohydrate Research</i> , 2005 , 340, 439-47 | 2.9 | 29 | |
| 65 | Energy state of chondrocytes assessed by 31P-NMR studies of preosseous cartilage. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 180, 216-22 | 3.4 | 29 | |
| 64 | Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004 , 44, 316-21 | 3.1 | 28 | |
| 63 | 31P NMR analysis of phospholipids in crude extracts from different sources: improved efficiency of the solvent system 1998 , 36, 907-912 | | 27 | |
| 62 | Cloning of the yeast ATP3 gene coding for the Eubunit of F1 and characterization of atp3 mutants <i>Journal of Biological Chemistry</i> , 1995 , 270, 2880 | 5.4 | 27 | |
| 61 | Hyaluronan can be protected from free-radical depolymerisation by 2,6-diisopropylphenol, a novel radical scavenger. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 193, 927-33 | 3.4 | 26 | |
| 60 | Levosimendan in Acute and Advanced Heart Failure: An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications. <i>Journal of Cardiovascular Pharmacology</i> , 2018 , 71, 129-136 | 3.1 | 23 | |
| 59 | Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 73, 3-14 | 3.1 | 22 | |
| 58 | Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. <i>PLoS ONE</i> , 2015 , 10, e0124742 | 3.7 | 22 | |
| 57 | Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017 , 243, 389-395 | 3.2 | 21 | |
| 56 | A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. <i>International Journal of Cardiology</i> , 2019 , 297, 83-90 | 3.2 | 21 | |
| 55 | Regulation of total mitochondrial Ca2+ in perfused liver is independent of the permeability transition pore. <i>American Journal of Physiology - Cell Physiology</i> , 1999 , 276, C1297-302 | 5.4 | 21 | |
| 54 | Use of levosimendan in acute heart failure. European Heart Journal Supplements, 2018, 20, I2-I10 | 1.5 | 21 | |
| 53 | Conformations of the regulatory domain of cardiac troponin C examined by residual dipolar couplings. <i>FEBS Journal</i> , 2000 , 267, 6665-72 | | 20 | |
| 52 | Structural investigation of the exopolysaccharide produced by Pseudomonas flavescens strain B62degradation by a fungal cellulase and isolation of the oligosaccharide repeating unit. <i>FEBS</i> Journal 1998, 251, 971-9 | | 19 | |

| 51 | Sensitivity of chondrocytes of growing cartilage to reactive oxygen species. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998 , 1425, 103-11 | 4 | 18 |
|----|--|------|----|
| 50 | 1H NMR spectroscopic studies of lipid extracts from human fatty liver. <i>Biochemical and Biophysical Research Communications</i> , 1993 , 192, 1217-22 | 3.4 | 18 |
| 49 | Energy metabolism, replicative ability, intracellular calcium concentration, and ionic channels of horse articular chondrocytes. <i>Experimental Cell Research</i> , 1994 , 210, 130-6 | 4.2 | 18 |
| 48 | Pharmaco-economics of levosimendan in cardiology: a European perspective. <i>International Journal of Cardiology</i> , 2015 , 199, 337-41 | 3.2 | 17 |
| 47 | Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. <i>Journal of Cardiovascular Pharmacology</i> , 2014 , 64, 199-208 | 3.1 | 17 |
| 46 | 31P NMR studies of resting zone cartilage from growth plate. <i>Magnetic Resonance in Medicine</i> , 1992 , 25, 355-61 | 4.4 | 17 |
| 45 | 1H-NMR studies of lipid extracts of rat liver mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 1991 , 179, 904-11 | 3.4 | 17 |
| 44 | Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 98, 74-8 | 3.1 | 16 |
| 43 | Lipid extracts from different algal species:1H and 13C-NMR spectroscopic studies as a new tool to screen differences in the composition of fatty acids, sterols and carotenoids. <i>Journal of Applied Phycology</i> , 1992 , 4, 315-322 | 3.2 | 15 |
| 42 | Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. <i>Cardiac Failure Review</i> , 2020 , 6, e19 | 4.2 | 15 |
| 41 | Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo. <i>Pharmacological Reports</i> , 2013 , 65, 1304-10 | 3.9 | 14 |
| 40 | Structure of the 1-36 N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17. <i>Biophysical Journal</i> , 2002 , 83, 484-90 | 2.9 | 14 |
| 39 | Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 76, 4-22 | 3.1 | 12 |
| 38 | Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. <i>Advances in Therapy</i> , 2012 , 29, 1037-50 | 4.1 | 12 |
| 37 | Absence of mitochondrial activation during levosimendan inotropic action in perfused paced guinea pig hearts as demonstrated by modular control analysis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2010 , 299, R786-92 | 3.2 | 12 |
| 36 | Modification of plasma membrane of differentiating preosseous chondrocytes: evidence for a degradative process in the mechanism of matrix vesicle formation. <i>Experimental Cell Research</i> , 1990 , 188, 214-8 | 4.2 | 12 |
| 35 | Long-term effects of Na /Ca exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019 , 21, 1543-1552 | 12.3 | 12 |
| 34 | Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1335-1347 | 2.5 | 11 |

| 33 | Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion. <i>European Journal of Pharmacology</i> , 2014 , 740, 539-51 | 5.3 | 11 |
|----|---|-----|----|
| 32 | Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012 , 110, 269-74 | 3.1 | 11 |
| 31 | Detection and quantitation of phosphorus metabolites in crude tissue extracts by 1H and 31P NMR: use of gradient assisted 1H-31P HMQC experiments, with selective pulses, for the assignment of less abundant metabolites. <i>NMR in Biomedicine</i> , 1995 , 8, 190-6 | 4.4 | 11 |
| 30 | Analysis of lipids in crude extracts by 13C nuclear magnetic resonance. <i>Analytical Biochemistry</i> , 1993 , 214, 238-44 | 3.1 | 11 |
| 29 | Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. <i>International Journal of Cardiology</i> , 2016 , 215, 26-31 | 3.2 | 11 |
| 28 | Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019 , 8, | 5.1 | 9 |
| 27 | Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H2007-14 | 5.2 | 9 |
| 26 | Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients. Journal of Clinical Medicine, 2020 , 9, | 5.1 | 8 |
| 25 | Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. <i>Cardiac Failure Review</i> , 2019 , 5, 155-161 | 4.2 | 8 |
| 24 | Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 389- | 395 | 8 |
| 23 | Novel Na/Ca Exchanger Inhibitor ORM-10962 Supports Coupled Function of Funny-Current and Na/Ca Exchanger in Pacemaking of Rabbit Sinus Node Tissue. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1632 | 5.6 | 6 |
| 22 | Inotropic effect of NCX inhibition depends on the relative activity of the reverse NCX assessed by a novel inhibitor ORM-10962 on canine ventricular myocytes. <i>European Journal of Pharmacology</i> , 2018 , 818, 278-286 | 5.3 | 6 |
| 21 | Possible mechanism of inhibition of cartilage alkaline phosphatase by insulin. <i>Acta Diabetologica Latina</i> , 1989 , 26, 321-7 | | 6 |
| 20 | Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats. <i>European Journal of Pharmacology</i> , 2015 , 750, 132-40 | 5.3 | 5 |
| 19 | 1H- and 13C-NMR spectroscopic studies of lipid extracts of the red algaGracilaria longa. <i>Journal of Applied Phycology</i> , 1992 , 4, 149-155 | 3.2 | 5 |
| 18 | Effects of Levosimendan on Inflammation and Oxidative Stress Pathways in a Lipopolysaccharide-Stimulated Human Endothelial Cell Model. <i>Biological Research for Nursing</i> , 2019 , 21, 466-472 | 2.6 | 4 |
| 17 | The clinical effects of levosimendan are not attenuated by sulfonylureas. <i>Scandinavian Cardiovascular Journal</i> , 2012 , 46, 330-8 | 2 | 4 |
| 16 | Short-term treatments for acute cardiac care: inotropes and inodilators. <i>European Heart Journal Supplements</i> , 2020 , 22, D3-D11 | 1.5 | 4 |

| 15 | An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 325-335 | 2.5 | 4 |
|----|--|-----|---|
| 14 | Complete structure analysis of OR-1746, a complex product of cyclocondensation of arylhydrazomalononitriles containing clusters of protonated and unprotonated nitrogens, by pulsed-gradient heteronuclear NMR. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003 , | 3.5 | 3 |
| 13 | ORM-3819 promotes cardiac contractility through Ca(2+) sensitization in combination with selective PDE III inhibition, a novel approach to inotropy. <i>European Journal of Pharmacology</i> , 2016 , 775, 120-9 | 5.3 | 3 |
| 12 | Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case. <i>Journal of Medical Economics</i> , 2016 , 19, 506-14 | 2.4 | 2 |
| 11 | Discovery and structural characterization of a phospholamban-binding cyclic peptide and design of novel inhibitors of phospholamban. <i>Chemical Biology and Drug Design</i> , 2013 , 81, 463-73 | 2.9 | 2 |
| 10 | Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed?. <i>International Journal of Cardiology</i> , 2013 , 168, 4798-9 | 3.2 | 2 |
| 9 | Levosimendan-induced venodilation is mediated by opening of potassium channels. <i>ESC Heart Failure</i> , 2021 , | 3.7 | 2 |
| 8 | Differential effects of inotropes and inodilators on renal function in acute cardiac care. <i>European Heart Journal Supplements</i> , 2020 , 22, D12-D19 | 1.5 | 2 |
| 7 | The Novel Inodilator ORM-3819 Relaxes Isolated Porcine Coronary Arteries: Role of Voltage-Gated Potassium Channel Activation. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 218-224 | 3.1 | 2 |
| 6 | The effect of levosimendan during long-term amiodarone treatment in dogs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006 , 99, 27-32 | 3.1 | 1 |
| 5 | Changed Relation between Phosphorylation Potential and Left Ventricular Developed Pressure in Guinea Pig Hearts during Ischemia-Reperfusion a. <i>Annals of the New York Academy of Sciences</i> , 1994 , 723, 495-502 | 6.5 | 1 |
| 4 | Calcium Sensitizer Levosimendan and Its Use in Acute Heart Failure and Related Conditions 2008 , 595-6 | 507 | 1 |
| 3 | Haemodynamic Effects of Levosimendan in Outpatients with Advanced Heart Failure: An Echocardiographic Pilot Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021 , | 3.1 | 1 |
| 2 | Levosimendan in Europe and China: An Appraisal of Evidence and Context. <i>European Cardiology Review</i> , 2021 , 16, e42 | 3.9 | |

Facing up to the challenges of acute heart failure. *European Heart Journal Supplements*, **2020**, 22, D1-D2 1.5